Atropine sulphate ophthalmic - Santen Pharmaceutical

Drug Profile

Atropine sulphate ophthalmic - Santen Pharmaceutical

Alternative Names: DE 127

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nanyang Technological University; SingHealth
  • Developer Santen Pharmaceutical
  • Class Alkaloids; Eye disorder therapies; Small molecules; Tropanes
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Myopia

Most Recent Events

  • 09 Nov 2017 Chemical structure added
  • 27 Oct 2017 Phase-II clinical trials in Myopia (In children) in Singapore (Ophthalmic) (NCT03329638)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top